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Summary
Mitral regurgitation (MR) involves systolic
retrograde flow from the left ventricle into the left
atrium. While trivial MR is frequent in healthy
subjects, moderate to severe MR constitutes the
second most prevalent valve disease after aortic
valve stenosis.Major causes of severeMR inWest-
ern countries include degenerative valve disease
(myxomatous disease, flail leaflet, annular calcifi-
cation) and ischaemic heart disease, while rheu-
matic disease remains a major cause of MR in de-
veloping countries. Chronic MR typically
progresses insidiously over many years. Once es-
tablished, however, severe MR portends a poor
prognosis. The severity of MR can be assessed by
various techniques, Doppler echocardiography
being the most widely used.Mitral valve surgery is
the only treatment of proven efficacy. It alleviates
clinical symptoms and prevents ventricular dilata-
tion and heart failure (or, at least, it attenuates
further progression of these abnormalities). Valve
repair significantly improves clinical outcomes
compared with valve replacement, reducing mor-
tality by approximately 70%. Reverse LV remod-
elling after valve repair occurs in half of patients
with functional MR. Percutaneous, catheter-based
mitral valve repair is a novel approach currently
under clinical scrutiny, with encouraging prelimi-
nary results.This modality may provide a valuable
alternative to mitral valve surgery, especially in
critically ill patients.
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Introduction
Over four million Europeans and a similar
number of Americans suffer from significant mi-
tral regurgitation (MR). Approximately 250000
new patients are diagnosed with the disease annu-
ally [1, 2]. The disorder generally evolves insidi-
ously over many years because the heart compen-
sates for the regurgitant volume by left atrial en-
largement, left ventricular (LV) volume overload,
and progressive LV dilatation. Older patients
(>50 years) with severe organic MR, defined as an
effective regurgitant orifice (ERO) area ≥40 mm
2
,
have 6% annual mortality (as compared with 3%
for moderate MR) [3].
The most common causes of MR include isch-
aemic heart disease, nonischaemic heart diseases
and valve degeneration. Both ischaemic (coronary
artery disease) and nonischaemic heart diseases
(e.g., idiopathic dilated cardiomyopathy) cause
“functional” MR via multiple different mecha-
nisms including impaired LV wall motion, LV dil-
atation, and papillary muscle displacement and
dysfunction. In contrast, degenerative (“organic”)
MR is caused by structural abnormalities of the
valve leaflets and the subvalvular apparatus, in-
cluding stretching or rupture of tendinous chords
(chordae tendineae).
Echocardiography plays a central role in the
assessment of MR.Valve surgery is the only treat-
ment for which sustained relief from symptoms
and prevention (or significant improvement) of
heart failure have been demonstrated. However,
elderly patients with MR fare less well after valve
surgery than those with aortic stenosis. Mortality
frommitral valve surgery, especially valve replace-
ment, is increased in older patients or in those
with concomitant coronary artery disease. Surgi-
cal mortality in the elderly (>75 years) is low in
experienced centres but exceeds 20% in less expe-
rienced centres [4].
Percutaneous catheter-based mitral valve
repair procedures are currently under clinical
evaluation. The preliminary results are encourag-
ing [5].
No ﬁnancial support
to declare.
37
SWISS MED WKLY 2010 ; 140 ( 3 –4 ) : 36–43 · www.smw.ch
Valve anatomy
The mitral valve apparatus consists of the an-
nulus, leaflets and tendinous chords attaching to
them, as well as papillary muscles anchoring the
chords (fig. 1). The normal mitral valve has two
leaflets: anterior and posterior. From an atrial view
(fig. 2a), the mitral annulus can be recognised as a
roughly elliptical line where the leaflets are
anchored to the atrioventricular junction in a
D-shaped configuration. The two leaflets are in
close contact at the closure line forming a single
zone of apposition which determines systolic
coaptation between the leaflets (fig. 2b). The two
leaflets are divided by two commisures. Small in-
dentations most often partition the posterior leaf-
let in three scallops (fig. 2c-d); however, four or
more scallops also are observed in a minority of
patients. The tendinous chords are fibrous string-
like structures attached to the ventricular surface
of the leaflets.They are classified as finer marginal
(primary) chords and thicker basal (secondary)
strut chords [6, 7]. Primary chords position the
leaflet tips and prevent prolapse. Secondary chords
insert symmetrically near the anterior leaflet base.
This classification has implications for mitral valve
repair.
Unlike the tricuspid valve, the mitral valve
does not have chords anchoring the leaflets to the
ventricular septum. The papillary muscles are
muscular protuberances of the LV wall anchoring
the chords to the wall itself. The anterolateral
papillary muscle is larger than the posteromedial
and is supplied with blood from either the left cir-
cumflex or the left anterior descending coronary
artery. Because most individuals exhibit a right-
dominant pattern of the coronary anatomy, the
posteromedial papillary muscle is in most cases
supplied with blood from the right coronary ar-
tery. Thus, ischaemia in the territory of the left
coronary artery frequently affects the anterola-
teral papillary muscle, whereas ischaemia in the
territory of the right coronary artery most often
affects the posteromedial papillary muscle.
Causes and mechanisms of MR
Both functional and organic abnormalities
causing MR do so by impairing the systolic coap-
tation between the anterior and posterior leaflet.
There are a multiplicity of different causes and
mechanisms for MR. A given cause is not invaria-
bly linked to the same mechanism; rather, it can
affect leaflet coaptation through different mecha-
nisms.
Causes of MR can be subdivided into non-
ischaemic and ischaemic (i.e., related to coronary
artery disease).
Mechanisms of MR can be subdivided into
functional (i.e., MR through a structurally normal
valve; e.g., caused by segmental LV wall motion
abnormalities, LV dilatation, papillary muscle
displacement and dysfunction) and organic (i.e.,
structural abnormalities of the leaflets or the sub-
valvular apparatus including the chords).
Carpentier introduced a functional classifica-
tion of MR based on leaflet movement (table 1):
Type I with normal leaflet movement (e.g., MR
caused by annular dilatation or leaflet perfora-
Figure 1
Anatomical specimen
of human mitral
valve consisting
of the papillary
muscles, tendinous
chords, and the
anterior and
posterior leaﬂet
(courtesy of Dr
Edgardo Bonacina,
Departmant of
Pathology, Ospedale
Niguarda-Cà Granda,
Milano, Italy;
reproduced with
permission from:
Faletra FF. Insufﬁ-
cienza mitralica.
Quaderni di ecograﬁa
clinica. 2004,
vol. 2, ERA Edizioni,
Castelseprio VA,
Italy).
Figure 2
Real-time 3DTEE view of the mitral annulus and leaﬂets
(atrial view); a) Mitral annulus (black arrows); b) Mitral valve;
closed position (black arrows: line of coaptation between
the two leaﬂets; asterisks: indentations between scallops).
PML = posterior mitral leaﬂet; AML= anterior mitral leaﬂet;
Ao = aorta; c1) Real-time 3DTEE image of mitral valve in
mid-diastole; c2 corresponding anatomical specimen (atrial
view). According to Carpentier, scallops of the posterior
and anterior leaﬂets are labelled P1, P2, P3 (from lateral to
medial) and A1, A2, A3, respectively (arrows: commissures
at the extremities of the coaptation line).
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tion); Type II with exaggerated leaflet movement
(e.g., mitral valve prolapse); andType IIIa and IIIb
with restricted leaflet movement in diastole and
systole, respectively.
Ischaemic MR is usually functional in nature
and chronic in presentation. Occasionally it is
caused by papillary muscle rupture, which is man-
ifested in acute clinical symptoms.After infarction,
the papillary muscles are displaced laterally, api-
cally and posteriorly, pulling the leaflet into the
left ventricle. Distortion is prominent in the basal
anterior leaflet, creating a bend (the “seagull sign”)
[7]. Papillary muscle dysfunction plays only a mi-
nor role compared with apical and inferior papil-
lary muscle displacement caused by ischaemic LV
remodelling and dilatation. Because tendinous
chords are not extensible, papillary muscle dis-
placement exerts traction on the leaflet, causing
tethering, apical leaflet displacement, and im-
paired coaptation between the two leaflets. To-
gether with annular flattening, enlargement, and
reduced contraction, mitral valve tenting affects
leaflet coaptation and causes functional MR.
Degenerative (organic) MR involves mitral
valve prolapse or, less frequently, calcifications of
the mitral annulus.
Mitral valve prolapse is an abnormal systolic
valve movement of one or both of the mitral leaf-
lets towards the left atrium (≥2 mm beyond the
saddle-shaped annular plane). Mitral valve pro-
lapse is twice as prevalent in females as in males;
however, severe MR caused by prolapse is more
frequent in older males than young females. Pro-
lapse is considered to be moderate when the leaf-
let tip remains in the left ventricle (billowing
valve), and severe when the leaflet tip bulges into
left atrium (flail leaflet).The latter is usually a con-
sequence of chordal rupture [8]. Structural abnor-
malities causing mitral prolapse include diffuse
myxomatous degeneration and primary flail leaflet
with ruptured chords.The latter affects the poste-
rior leaflet in 70% of cases. It can be associated
with myxomatous degeneration restricted to the
flail portion of the leaflet.
Rheumatic MR causes retraction of tendinous
chords and leaflets, as well as annular dilatation,
thus compromising coaptation between the two
leaflets. Similar changes are observed in postin-
flammatory and postradiotherapy MR. Infectious
endocarditis can cause MR through chordal rup-
ture or leaflet perforation.
Table 1
Causes and
mechanisms of mitral
regurgitation.
Cause Mechanism
Organic Functional
Type I Type II Type IIIa Type I/IIIb
Nonischaemic Endocarditis (perforation);
degenerative (annular
calcification); congenital
(cleft leaflet)
Degenerative (mitral
valve prolapse, flail
leaflet); endocarditis
(ruptured chords)
Rheumatic; iatrogenic
(radiation/drug);
inflammatory
(lupus, anticardiolipin);
etc.
Cardiomyopathy;
myocarditis; left
ventricular
dysfunction
(any cause)
Ischaemic Ruptured PM Functional ischaemic
MR = mitral regurgitation. PM = papillary muscle. Classification according to Carpentier: Type I: normal leaflet movement;
Type II: excessive leaflet movement; Type III: restricted leaflet movement (IIIa in diastole, IIIb in systole).
Pathophysiology and natural history
The regurgitant volume depends upon the re-
gurgitant orifice and the systolic pressure gradient
between left ventricle and atrium [9]. Thus, the
observed degree of MR depends on haemody-
namic conditions at the time of examination. Any
increase in preload or afterload, and any decrease
in myocardial contractility, causes LV dilatation,
enlargement of the mitral annulus, and an increase
in ERO. In acute MR the atrium is noncompliant,
and therefore mechanical energy generated by the
left ventricle causes an increase in intra-atrial
pressure. In chronic MR the atrium is more com-
pliant, and therefore mechanical energy generated
by the ventricle causes volume overload and atrial
enlargement rather than an increase in intra-
atrial pressure. Consequently, chronic MRmay be
associated with a small regurgitation wave (the so-
called V-wave).
Progression of organic MR is associated with
an increase in regurgitant volume by 5–7 ml per
year. This is manifested by a progressive increase
in ERO area due to valvular degeneration and an-
nular enlargement [10]. Patients with chronic MR
often remain asymptomatic for many years. Over
time, however, the left ventricle dilates to accom-
modate the increased volume load and maintain
cardiac output. Chronic LV volume overload leads
to contractile dysfunction, heart failure and in-
creased risk of sudden death. Patients with severe,
symptomatic MR have a poor prognosis, with a
5% annual mortality if valve surgery is not per-
formed. Progressive heart failure is the most com-
mon cause of death in these patients, while sudden
death, stroke, and fatal endocarditis are less fre-
quent. Asymptomatic or minimally symptomatic
patients with severe MR secondary to mitral valve
prolapse and normal LV function at rest have an
annual risk of undergoing valve surgery of approx-
imately 10%, mainly due to the appearance of
clinical symptoms [11].
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Echocardiography plays a central role in the
assessment of the mechanism and the severity of
MR, as well as of the feasibility of valve repair ver-
sus replacement. In severe MR, transthoracic
echocardiography (TTE) shows left atrial and
ventricular enlargement. LV systolic motion may
be increased in the compensatory phase of chronic
MR. Peak mitral flow velocity is increased and
flow in the pulmonary veins during systole may be
reversed. Echocardiography is very useful for
identifying the mechanism of MR, e.g., chordal
rupture, valve prolapse, rheumatic disease, a flail
leaflet, endocarditis or LV dilatation. Calcification
of the mitral annulus is visible as a high-density
structure between the mitral apparatus and the
posterior LV wall.
Transoesophageal echocardiography (TEE) is
superior toTTE for assessing the precise anatomy
of the valve and MR severity. TEE is mandatory
when transthoracic images are of suboptimal qual-
ity (fig. 3) [12], as well as for pre- and perioperative
valve assessment. Real-time three-dimensional
(3D) TTE or TEE provides a comprehensive im-
aging of the mitral valve. 3D TEE images mimic
the view of the valve through the left atrium at
surgery (fig. 2). This method allows a precise as-
sessment of anatomical structures (e.g., the mitral
annulus), which cannot be easily evaluated by 2D
modalities.
Quantitative methods for assessing the sever-
ity of MR include vena contracta and the proximal
isovelocity surface area (PISA) method [13]. Vena
contracta is defined as the narrowest cross-sectional
area of the regurgitant jet determined by colour
flow Doppler echocardiography. It correlates well
with the severity of MR. The PISA method is
based on the acceleration of the regurgitant flow
towards the mitral orifice. This flow can be
mapped as isovelocity hemispheric shells. ERO
area ≥40 mm
2
and regurgitant volume ≥60 ml in-
dicate severeMR.These methods have prognostic
value.
Assessment of MR
Figure 3
TEE long-axis view
showing severe MR
due to tethering of
the posterior mitral
leaﬂet (functional,
ischaemic MR).
Treatment
The impact of different treatments on survival
rates has not been evaluated in randomised clini-
cal trials; hence, it can only be estimated from out-
come studies [14].
Medical treatment
Pharmacological treatment aims to alleviate
symptoms and slow down progression of LV dys-
function. In acute MR, nitrates and diuretics re-
duce filling pressures. Nitroprusside reduces af-
terload and hence regurgitant fraction. Inotropic
agents may be beneficial in patients with heart
failure and hypotension. Patients with MR and
permanent or paroxysmal atrial fibrillation, and
patients with a history of systemic thromboem-
bolism or evidence for a left atrial thrombus
should receive anticoagulant therapy with a target
international normalised ratio (INR) of 2–3 units
[14]. Anticoagulant therapy is also required after
mitral valve repair (3 months). In contrast, there is
no evidence to support the use of vasodilators, in-
cluding ACE inhibitors, in chronic MR in the ab-
sence of heart failure [15]. Once heart failure is es-
tablished, however, ACE inhibitors are beneficial.
They can be used in patients with advanced MR
and severe symptoms who are poor candidates for
surgery and in patients who remain symptomatic
after surgery due to LV dysfunction. Beta-blocker
and spironolactone may also be beneficial in pa-
tients with heart failure. According to new guide-
lines, endocarditis prophylaxis forMR is no longer
required; however, it is still mandatory after mitral
valve repair (6 months) or mitral valve replace-
ment [16].
Surgical treatment
Mitral valve surgery is the only treatment for
MR which provides sustained relief of symptoms
and prevents the development (or further progres-
sion) of heart failure [17]. However, no ran-
domised trials have been carried out to define the
precise impact of surgery on mortality and mor-
bidity in these patients. Criteria for mitral valve
surgery are summarised in table 2.
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Mitral valve repair is superior to valve replace-
ment in terms of both mortality and morbidity,
and is therefore preferable whenever feasible [17].
This approach includes an array of valvular, sub-
valvular, and annular procedures aiming to restore
leaflet coaptation, i.e., valvular normal function.
Overall these techniques are more effective in the
presence of redundant, as opposed to retracted or
calcified, leaflets.
Surgical repair for valve prolapse
A typical repair technique for prolapse of a
posterior leaflet consists of triangular or quadran-
gular resection of the prolapsed leaflet segment in
conjunction with posterior annulus plication su-
tures (fig. 4a). Subvalvular support can be achieved
by chordal transfer or artificial chords rather than
chordal shortening. Annuloplasty is routinely per-
formed by the use of annular bands and either
flexible or rigid rings. Prosthetic rings reconstitute
and stabilise the correct shape of the annulus and
the repaired valve; they therefore represent a
mandatory part of mitral valve reconstruction.
Surgical repair for anterior leaflet prolapse is
more challenging than that for posterior leaflet
prolapse. Reconstructive techniques for anterior
leaflet prolapse include replacement, shortening
or transposition of chords, reinforcement with ar-
tificial chords, leaflet-folding plasty and triangular
resection [18]. Overall, long-term outcomes of
mitral valve repair for anterior leaflet prolapse are
satisfactory [18]. Early valve repair of MR caused
by leaflet prolapse, before deterioration in LV size
or function, increases the likelihood of postopera-
tive normalisation of LV ejection fraction [19].
Class I
Symptomatic patient with acute severe MR
Chronic severe MR and NYHA functional class II, III or IV symptoms in the absence of severe LV dysfunction (LVEF <30%) and/or
ESD >55 mm
Asymptomatic patients with chronic severe MR and mild to moderate LV dysfunction, LVEF 30–60%, and/or ESD >40 mm
Valve repair is recommended (superior to valve replacement)
Class IIa
Valve repair is reasonable in experienced surgical centres for asymptomatic patients with chronic severe MR with preserved LV function
(LVEF >60% and ESD <40 mm) in whom the likelihood of successful repair without residual MR is >90% (IIb in the guidelines of the
European Society of Cardiology)
Valve surgery is reasonable for asymptomatic patients with chronic severe MR, preserved LV function, and:
New onset of atrial fibrillation
Pulmonary hypertension (PASP >50 mm Hg at rest or >60 mm Hg during exercise)
Valve surgery is reasonable for patients with chronic severe MR due to primary abnormalities of the mitral apparatus, NYHA functional
class III-IV, and severe LV dysfunction (LVEF <30% and/or ESD >55 mm) in whom valve repair is highly likely
Class IIb
Valve repair can be considered for patients with chronic severe secondary MR due to severe LV dysfunction (LVEF <30%) persistently
in NYHA functional class III–IV despite optimum therapy for heart failure, including biventricular pacing
Class III
Valve surgery is not indicated for asymptomatic patients with MR and preserved LV function (LVEF >60% and ESD <40 mm) in whom
significant doubt about the feasibility of repair exists
Isolated MV surgery is not indicated for patients with mild to moderate MR
Abbreviations: ESD: endsystolic diameter; LVEF: left ventricular ejection fraction; PASP: pulmonary artery systolic pressure
Table 2
Indications for mitral
valve surgery.
Figure 4
Left panel: Classical
quadrangular
resection for mitral
valve prolapse.
Right panel): New
ring design aimed at
improving annular
support.
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Valve repair for functional MR
In functional MR, valve repair rather uni-
formly includes remodelling of the distorted an-
nulus with a prosthetic ring also aiming to reduce
the antero-posterior annular diameter. Ring annu-
loplasty is usually sufficient for nonischaemic
functional MR.
Surgery for ischaemic functional MR is more
demanding. This is mainly due to the sequelae of
ischaemic heart disease (regional or diffuse hypo-/
akinesia, ventricular dilatation, ventricular dys-
function) and the tethering of the posterior leaflet
usually present due to apical and posterolateral
displacement of the papillary muscles following
myocardial infarction and ventricular remodel-
ling.The common denominator of all surgical ap-
proaches is restrictive (undersized) annuloplasty
with a rigid or semirigid ring. Additional proce-
dures specifically address the tethering of the pos-
terior leaflet and include papillary muscle reloca-
tion by traction sutures or cutting of second order
chordae of the posterior leaflet. So-called saddle-
shaped annuloplasty rings (e.g., Geoform
®
rings)
have recently been developed to address this prob-
lem [20]. These rings induce upward traction on
the affected papillary muscle towards the mitral
annulus. Initial data in patients with ischaemic
MR show that mitral valve annuloplasty using the
Geoform
®
ring restores leaflet coaptation and
eliminates MR by effectively modifying the mitral
annular geometry [21].
Centres with wide experience in mitral valve
repair report 80–90% success rates [3]. LV reverse
remodelling after mitral valve repair was observed
in half of patients with functional MR and ischae-
mic or idiopathic dilated cardiomyopathy [22]. It
was associated with longer repair durability and a
better clinical outcome than in patients with per-
sistence or progression of the remodelling pro-
cess. Predictors of reverse remodelling are a pre-
operative LV enddiastolic diameter <65 mm and a
generous coaptation surface between anterior and
posterior leaflet after restrictive annuloplasty (co-
aptation height >8 mm) [23]. Continued LV re-
modelling contributes to recurrent regurgitation
after annuloplasty [24], which is observed in 20–
30% of patients after surgical valve repair for post-
infarction MR [25]. Careful indication and choice
of the surgical procedure, as well as attention to
technical details, contribute to improved results
[23].
Valve replacement
Valve replacement involves implantation of a
biological or mechanical prosthesis. Bioprosthetic
valves are associated with lower thromboembolic
risk but limited longevity compared with mechan-
ical ones. On the other hand, mechanical valves
are associated with increased risk of thrombo-em-
bolism, which mandates chronic anticoagulant
therapy, with an associated increased risk of haem-
orrhagic complications [14, 26]. Considering the
theoretical longevity of prosthetic valves, biopros-
theses are generally preferred in patients over 65.
It is obviously important to discuss the choice of
the prosthesis with the patient.
Outcome after surgery
Clinical outcomes after mitral valve surgery
depend on patient- and disease-specific factors, as
well as on surgery-related factors. In-hospital
morbidity and mortality for first time mitral valve
repair and replacement surgery are listed in table
3. Early postoperative mortality is significantly af-
fected by age. However, improvement of surgical
techniques in experienced centres has resulted in
mortality rates of ≈1%, 2%, and 4–5% for patients
under 65, aged 65–75, and over 75 respectively
[27]. Major surgery-related determinants of the
operative risk include the surgical procedure used
(i.e., valve repair versus replacement) and the need
for concomitant CABG surgery [28].
Patients with advanced heart failure generally
have a poor prognosis, particularly in the case of
functional MR. In a recent study, 5-year survival
rates in non-operated patients with ischaemic MR
were 38% and 29% in the presence of ERO area
< or >20 mm
2
respectively [29]. In a separate high-
risk population with post-infarction ischaemic
cardiomyopathy treated by surgical ventricular
restoration (SVR) and mitral valve repair, 5-year
survival was 62% [30]. The effectiveness of SVR,
alone or in conjunction with coronary artery by-
pass grafting (CABG) in patients with ischaemic
heart disease and anterior LV dysfunction is under
evaluation by the Surgical Treatment for Ischemic
Heart Failure (STICH) trial [31].
Management of asymptomatic severe MR
The management of asymptomatic patients
with severe MR remains controversial. A study in
asymptomatic patients with floppy valves reported
improved late outcomes after mitral valve repair
[32]. On the other hand, a series of 132 consecu-
tive asymptomatic patients (age 55 ± 15 years, 49
female) with severe degenerative MR treated by a
“watchful waiting” approach showed 6% mortal-
ity at 5 years [32]. Survival free of any indication
for surgery was 92 ± 2% at 2 years, 78 ± 4% at 4
years, 65 ± 5% at 6 years, and 55 ± 6% at 8 years.
These data suggest that, in general, asymptomatic
patients with severe degenerative MR can be
safely followed up until either symptoms occur or
currently recommended cutoff values for LV size,
LV function, or pulmonary hypertension are
Table 3
In-hospital morbidity
and mortality for ﬁrst
time isolated mitral
valve surgery
(STS 2008).
Complication Mitral valve repair Mitral valve
replacement
Death 1.1% 6.3%
Stroke 2.2% 3.8%
Renal failure 1.8% 6.9%
Prolonged ventilation 9.5% 22.9%
Perioperative MI 1.4% 1.7%
Reoperation
– any
– bleeding
– other cardiac
5.2%
2.3%
0.8%
11.3%
5.1%
2.2%
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reached. However, this management requires
careful follow-up.
In selected patients with advanced heart fail-
ure, Chronic resynchronisation therapy (CRT).
attenuates MR, improves cardiac output and alle-
viates symptoms [34].
Percutaneous, catheter-based mitral valve re-
pair includes leaflet (edge-to-edge) repair and mi-
tral annular reduction.These approaches have not
yet been approved for clinical use, but remain
largely investigational.
Percutaneous edge-to-edge repairmimics the sur-
gical procedure originally proposed byAlfieri [35].
It aims to create a tissue bridge between the ante-
rior and the posterior leaflet by clip deployment
via transseptal catheterisation (fig. 5 and 6). Pre-
liminary data are encouraging, with ≈80% of pa-
tients showing mild or trace MR at hospital dis-
charge [36]. Moreover, 12-month follow-up data
from the High-Risk Registry Arm of the North
American EVEREST II study suggest that high-
risk patients with functional or degenerative MR
may benefit substantially from mitral clips in
terms of morbidity and mortality [37].
Percutaneous mitral annular reduction aims to
reduce annular dilatation.This approach generally
includes coronary sinus cinching. It has been
shown to attenuate MR in animal models [38], but
the clinical data are preliminary. Achieving a con-
straining force resulting in >20% diameter reduc-
Figure 5
Percutaneous mitral
clip device (Mitra-
Clip
®
System)
introduced by venous
and transseptal
approach into the left
atrium and through
the mitral oriﬁce.
The arms of the clip
delivery system are
open to grasp the
two leaﬂets following
positioning of the
device centered over
the origin of the
regurgitant jet
(ﬁg. 6c).
Figure 6
Step-by-step percutaneous edge-to-edge repair (left panel:
cartoon provided by the supplier; right panel: real-time 3D
TEE); a) guide-wire introduced into the left atrium; b) clip
delivery system deployed over the mitral oriﬁce; c) arms of
clip delivery system oriented perpendicularly to long axis of
leaﬂet edge; d) clip delivery system anchored to mitral
leaﬂets; e) ﬁnal result (long axis view).
tion is challenging from a technical standpoint.
This procedure includes anchoring devices that
are placed in the distal and proximal coronary si-
nus, and an intermediate tensioning or supporting
element.A practical limitation is that these devices
occupy the space where biventricular pacing leads
are frequently positioned for CRT.
Conclusions
MR imposes volume overload on the left
atrium and ventricle, eventually resulting in their
progressive dilatation, atrial fibrillation, and heart
failure. Pharmacological therapy provides limited
symptomatic benefit. Timely mitral valve repair
prevents development or further progression of
LV dysfunction. Reverse LV remodelling after
valve repair occurs in half of patients with func-
tional MR. This approach is the treatment of
choice for moderate to severe MR but is not feasi-
ble in patients with advanced degenerative abnor-
malities of the valve. Functional (secondary) MR
results from regional LV dysfunction, most often
in the context of ischaemic heart disease.Although
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surgical mortality has declined in the past decade,
long-term outcomes remain poor. The manage-
ment of secondary MR includes pharmacological
therapy of heart failure and CRT in selected pa-
tients. Surgical approaches to secondary MR need
to be optimised. Ongoing clinical trials will prob-
ably provide new insights into the safety and effi-
cacy of percutaneous mitral valve repair.
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